Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H446
UPID:
RWDD1_HUMAN
Alternative names:
DRG family-regulatory protein 2
Alternative UPACC:
Q9H446; A8K3W2; A8MT24; Q9Y313; Q9Y6B3
Background:
RWD domain-containing protein 1, alternatively known as DRG family-regulatory protein 2, plays a crucial role in cellular processes by protecting DRG2 from proteolytic degradation. This protein's unique function highlights its importance in maintaining cellular integrity and function.
Therapeutic significance:
Understanding the role of RWD domain-containing protein 1 could open doors to potential therapeutic strategies. Its pivotal role in protecting DRG2 underscores its potential as a target for drug discovery, aiming to harness its protective functions for therapeutic benefits.